EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Survivin Interference and SurVaxM as an Adjunct Therapy for Glioblastoma Multiforme

Willie James Elliott, Nandini Gurramkonda, Maheedhara R Guda, Andrew J Tsung iD, Kiran K Velpula iD

Cells · 2025

DOI: 10.3390/cells14100755 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, 2025. Verfasst von Willie James Elliott und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Biology and Pharmacology, University of Illinois College of Medicine Peoria, Peoria, IL 61605, USA. Hauptthemen laut MEDLINE: Glioblastoma, Survivin, Cancer Vaccines, Brain Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma, IDH wild-type WHO Grade IV, is a devastating diagnosis in pediatric and adult populations with a poor prognosis and median overall survival of less than two years. Despite the advent of the Stupp protocol and advances in neurosurgical tumor resection techniques, there has been minimal change to both the quantity and quality of life in individuals diagnosed. Provided the extensive research on survivin’s association with glioblastoma tumor microenvironment, this review suggests that priming the individual’s immune systems to the tumor-promoting protein may reduce tumor burden through multiple mechanisms, including the arrest of the G2/M phase, microtubule dysfunction, induction of autophagy, and ultimately activation of apoptosis in glioblastoma cells. SurVaxM, a multiple peptide, survivin-specific vaccine, may assist in tumor cell destruction by eliciting the production of cytotoxic T-cells specific to survivin-expression glioblastoma tumors. Although phase I and II clinical trials suggest relatively safe adverse effects and potential efficacy, additional research is necessary to evaluate further how this vaccine may compare to standard treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaSurvivinCancer VaccinesBrain NeoplasmsHumansAnimals

Stichwörter der Autor:innen

Baculoviral IAP repeat containing 5 (BIRC5)SurVaxMglioblastoma (GBM)surviving

Substanzen

SurvivinCancer VaccinesBIRC5 protein, human

Autor:innen und Institutionen

  • Department of Cancer Biology and Pharmacology, University of Illinois College of Medicine Peoria, Peoria, IL 61605, USA.
  • Department of Neurosurgery, University of Illinois College of Medicine Peoria, Peoria, IL 61605, USA.
  • Illinois Neurological Institute, Peoria, IL 61605, USA.
  • Department of Pediatrics, University of Illinois College of Medicine Peoria, Peoria, IL 61605, USA.

ORCID-Profile: Andrew J Tsung, Kiran K Velpula

Zitieren

APA

Elliott, W. J., Gurramkonda, N., Guda, M. R., Tsung, A. J., & Velpula, K. K. (2025). Survivin Interference and SurVaxM as an Adjunct Therapy for Glioblastoma Multiforme. Cells. https://doi.org/10.3390/cells14100755

Vancouver

Elliott WJ, Gurramkonda N, Guda MR, Tsung AJ, Velpula KK. Survivin Interference and SurVaxM as an Adjunct Therapy for Glioblastoma Multiforme. Cells. 2025. doi:10.3390/cells14100755

BibTeX
@article{Elliott2025,
  author = {Elliott, Willie James and Gurramkonda, Nandini and Guda, Maheedhara R and Tsung, Andrew J and Velpula, Kiran K},
  title = {Survivin Interference and SurVaxM as an Adjunct Therapy for Glioblastoma Multiforme},
  journal = {Cells},
  year = {2025},
  doi = {10.3390/cells14100755}
}
Kostenlos starten →